Morgan Stanley Upgrades ResMed (RMD) to Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/8/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- Atlassian results seen as 'game changer' for AI kills software worries
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Microsoft only US hyperscaler with positive free cash flow as AI capex bites
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
ResMed (RMD) PT Bumped to $66 at Needham & Company Posts Q4
July 31, 2015 8:02 AM EDTNeedham & Company analyst Mike Matson reiterated a Buy rating and raised his price target on ResMed (NYSE: RMD) to $66.00 (from $65.00) following solid Q4 results driven by flow generator product cycle.
Matson commented, "RMD's revenue and EPS beat consensus as its revenue... More
Deutsche Bank Downgrades ResMed (RMD) to Sell
July 31, 2015 7:32 AM EDTDeutsche Bank downgraded ResMed (NYSE: RMD) from Hold to Sell with a price target of $53.00 (from $61.00). The change follows Q4 results. Analyst David Low noted strong sales offset by GM weakness.
"After the incredible success of ResMeds AirSense range we are wary FY16... More
ResMed (RMD) Tops Q4 EPS by 3c, Revenue Beats
July 30, 2015 4:52 PM EDTResMed (NYSE: RMD) reported Q4 EPS of $0.68, $0.03 better than the analyst estimate of $0.65. Revenue for the quarter came in at $453.1 million versus the consensus estimate of $436.73 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
... More